blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2964214

EP2964214 - USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  01.12.2023
Database last updated on 02.11.2024
FormerGrant of patent is intended
Status updated on  15.03.2023
FormerExamination is in progress
Status updated on  27.09.2019
Most recent event   Tooltip01.12.2023Application deemed to be withdrawnpublished on 03.01.2024  [2024/01]
Applicant(s)For all designated states
ALLERGAN, INC.
2525 Dupont Drive
Irvine, CA 92612 / US
[2016/02]
Inventor(s)01 / VISWANATH, Veena
29 Clocktower
Irvine, California 92620 / US
02 / BEARD, Richard L.
2341 Azure Avenue
Newport Beach, California 92660 / US
03 / DONELLO, John E.
34041 Pequito Drive
Dana Point, California 92629 / US
04 / HSIA, Edward C.
21 Ensueno West
Irvine, California 92620 / US
 [2016/02]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2016/02]
Application number, filing date14713302.904.03.2014
[2016/02]
WO2014US20273
Priority number, dateUS201361773778P06.03.2013         Original published format: US 201361773778 P
[2016/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014138046
Date:12.09.2014
Language:EN
[2014/37]
Type: A1 Application with search report 
No.:EP2964214
Date:13.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 12.09.2014 takes the place of the publication of the European patent application.
[2016/02]
Search report(s)International search report - published on:EP12.09.2014
(Supplementary) European search report - dispatched on:EP01.10.2019
ClassificationIPC:A61K31/17, A61K31/196, A61K31/4166, A61K31/42, A61K31/662, A61P17/02, A61P17/04, A61P17/06, A61P17/08, A61P17/10, A61P17/12, A61P17/14, A61P17/16, A61P17/18, A61P35/00
[2023/12]
CPC:
A61K31/196 (EP,CN,KR,US); A61K31/17 (KR,US); A61K31/683 (US);
A61K31/167 (US); A61K31/192 (US); A61K31/197 (CN);
A61K31/4045 (US); A61K31/405 (CN); A61K31/41 (US);
A61K31/4166 (EP,KR,US); A61K31/4174 (US); A61K31/4178 (US);
A61K31/4184 (US); A61K31/42 (EP,KR,US); A61K31/472 (US);
A61K31/4725 (US); A61K31/55 (US); A61K31/662 (EP,KR,US);
A61K9/0014 (US); A61P17/02 (EP,US); A61P17/04 (EP,US);
A61P17/06 (EP,US); A61P17/08 (EP,US); A61P17/10 (EP,US);
A61P17/12 (EP,US); A61P17/14 (EP,US); A61P17/16 (EP,US);
A61P17/18 (EP,US); A61P35/00 (EP,US); C07C235/82 (KR,US);
C07C275/42 (KR,US); C07D217/24 (EP,KR,US); C07D223/10 (EP,KR,US);
C07D233/80 (EP,KR,US); C07D235/02 (EP,US); C07D257/04 (EP,US);
C07D261/12 (EP,US); C07D401/06 (EP,US); C07D405/06 (EP,US);
C07D405/14 (EP,US); C07D409/06 (EP,US); C07F9/40 (KR,US) (-)
Former IPC [2016/02]A61K31/17, A61K9/00, A61K31/196, A61K31/4166, A61K31/42, A61K31/662, A61P17/00, A61P17/06, A61P17/10, A61P17/12, A61P17/14, A61P17/18, A61P17/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/02]
TitleGerman:VERWENDUNG VON AGONISTEN DES FORMYLPEPTIDREZEPTORS 2 ZUR BEHANDLUNG VON HAUTEKRANKUNGEN[2016/02]
English:USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES[2016/02]
French:UTILISATION D'AGONISTES DU RÉCEPTEUR 2 DE PEPTIDE FORMYLE POUR LE TRAITEMENT DE MALADIES DERMATOLOGIQUES[2016/02]
Entry into regional phase07.08.2015National basic fee paid 
07.08.2015Designation fee(s) paid 
07.08.2015Examination fee paid 
Examination procedure07.08.2015Examination requested  [2016/02]
13.04.2016Amendment by applicant (claims and/or description)
01.10.2019Despatch of a communication from the examining division to which search results under Rule 164(2) EPC are annexed (Time limit: M04) [2019/45]
01.10.2019Despatch of a communication from the examining division (Time limit: M04)
04.02.2020Reply to a communication from the examining division
21.12.2020Despatch of a communication from the examining division (Time limit: M02)
24.02.2021Reply to a communication from the examining division
16.03.2023Communication of intention to grant the patent
27.07.2023Application deemed to be withdrawn, date of legal effect  [2024/01]
17.08.2023Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2024/01]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  01.10.2019
Fees paidRenewal fee
31.03.2016Renewal fee patent year 03
27.03.2017Renewal fee patent year 04
27.03.2018Renewal fee patent year 05
27.03.2019Renewal fee patent year 06
27.03.2020Renewal fee patent year 07
29.03.2021Renewal fee patent year 08
16.03.2022Renewal fee patent year 09
Penalty fee
Additional fee for renewal fee
31.03.202310   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO0114328  (MERCK & CO INC [US], et al) [A] 1-4 * abstract * * compound on page 14, second table, entry 7-8 ** page 1, line 20 *;
 [A]KR20090121832  (UNIV INJE IND ACAD COOPERATION [KR]) [A] 1-4 * abstract *;
 [X]US2012142726  (BEARD RICHARD L [US], et al) [X] 1,2 * abstract * * paragraph [0002] *;
 [A]WO2013009543  (ALLERGAN INC [US], et al) [A] 1-4 * abstract *;
 [XDP]WO2013070600  (ALLERGAN INC [US], et al) [XDP] 1-4 * abstract * * page 26, lines 15-20 *;
 [X]  - TSURUKI T ET AL, "Orally administered FPRL1 receptor agonist peptide MMK-1 inhibits etoposide-induced alopecia by a mechanism different from intraperitoneally administered MMK-1", PEPTIDES, ELSEVIER, AMSTERDAM, NL, vol. 27, no. 4, ISSN 0196-9781, (20060401), pages 820 - 825, (20060401), XP027957734 [X] 1,2 * abstract *
ExaminationWO0158932
 WO2010056778
 WO2013062947
 WO2013071203
 EP3103797
 EP2770989
by applicantJPS63232846
 US2005137230
 US7820673
    - CHIANG N; SERHAN CN; DAHLEN, S; DRAZEN JM; HAY DWP; ROVATI E; SHIMIZU T; YOKOMIZO T; BRINK, C., "The lipoxin receptor ALX: Potent ligand-specific and stereoselective actions in vivo", PHARMACOLOGICAL REVIEWS, (2006), vol. 58, pages 463 - 519
    - CHIANG N; SERHAN CN; DAHLEN, S; DRAZEN JM; HAY DWP; ROVATI E; SHIMIZU T; YOKOMIZO T; BRINK, C., "The lipoxin receptor ALX: Potent ligand-specific and stereoselective actions in vivo.", PHARMACOLOGICAL REVIEWS, (2006), vol. 58, pages 463 - 519
    - DUFTON N; PERRETTI M., "Therapeutic anti-inflammatory potential of formyl peptide receptor agonists.", PHARAMCOLOGY & THERAPEUTICS, (2010), vol. 127, pages 175 - 188, XP027117295
    - DUFTON N; HANNON R; BRANCALEONE V; DALLI J; PATEL HB; GRAY M; D'AQUISTO F; BUCKINGHAM JC; PERRETTI M; FLOWER RJ., "Anti-inflammatory role of the murine formyl-peptide receptor 2: Ligand-specific effects on leukocyte responses and experimental inflammation.", JOURNAL OF IMMUNOLOGY, (2010), vol. 184, pages 2611 - 2619
    - GAVINS FNE; HUGHES EL; BUSS NAPS; HOLLOWAY PM; GETTING SJ; BUCKINGHAM JC., "Leukocyte recruitment in the brain in sepsis: involvement of the annexin1 FPR2/ALX anti-inflammatory system.", FASEB, (2012), vol. 26, pages 1 - 13
    - MADERNA P; COTTELL DC; TOIVONEN T; DUFTON N; DALLI J; PERRETTI M; GODSON C., "FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.", FASEB, (2010), vol. 24, doi:doi:10.1096/fj.10-159913, pages 4240 - 4249, XP055022195

DOI:   http://dx.doi.org/10.1096/fj.10-159913
    - REVILLE K; CREAM JK; VIVERS S; DRANSFIELD , GODSON C., "Lipoxin A4 redistributes Mysoin IIA and Cdc42 in macrophages: Implications for phagocytosis of apoptotic leukocytes.", JOURNAL OF IMMUNOLOGY, (2006), vol. 176, pages 1878 - 1888
    - SERHAN C., "Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways.", ANNUAL REVIEWS OF IMMUNOLOGY, (2007), vol. 25, pages 101 - 137
    - TAKANO T; FIORE S; MADDOX JF; BRADY HR; PETASIS NA; SERHAN CN., "Asprin-triggered 15-epi-lipoxin A4 and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors", JOURNAL OF EXPERIMENTAL MEDICINE, (1997), vol. 185, doi:doi:10.1084/jem.185.9.1693, pages 1693 - 1704, XP002141526

DOI:   http://dx.doi.org/10.1084/jem.185.9.1693
    - LEONI G; ALAM A; NEUMANN PA; LAMBETH JD; CHENG G; MCCOY J; HILGARTH RS; KUNDU K; MURTHY N; KUSTERS D, "Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair", JOURNAL OF CLINICAL INVESTIGATION., (2013), vol. 123, pages 443 - 54
    - LEEDOM A; SULLIVAN AB; DONG B; LAU D; GRONERT K., "Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury", AMERICAN JOURNAL OF PATHOLOGY, (2010), vol. 176, pages 74 - 84
    - TSURUKI T; TAKAHATA K; YOSHIKAWA M., "Mechanism of the protective effect of intraperitoneally administered agonists for formyl peptide receptors against chemotherapy-induced alopecia", BIOSCI BIOTECHNOLOGY BIOCHEMISTRY, (2007), vol. 71, pages 1198 - 202
    - YAMASAKI K; DI NARDO A; BARDAN A; MURAKAMI M; OHTAKE T; CODA A; DORSCHNER RA; BONNART C; DESCARGUES P; HOVNANIAN A, "Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea.", NATURE MEDICINE, (2007), vol. 13, doi:doi:10.1038/nm1616, pages 975 - 80, XP002616691

DOI:   http://dx.doi.org/10.1038/nm1616
    - JOURNAL OF CHROMATOGRAPHY, (1987), vol. 404, no. 1, pages 117 - 22
    - CHROMATOGRAPHIA, (1987), vol. 23, no. 10, pages 727 - 30
    - BIOCHIMICA ET BIOPHYSICA ACTA, NUCLEIC ACIDS AND PROTEIN SYNTHESIS, (1972), vol. 272, no. 4, pages 667 - 71
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.